Sarah Bos

61 Anticoagulant activity of edoxaban in patients with cirrhosis 4 inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–41. 17. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016;38(5):505–13. 18. Lip GYHH, Agnelli G. Edoxaban: A focused review of its clinical pharmacology. Eur Heart J. 2014;35(28):1844–55. 19. Weinberg EM, Palecki J, Reddy KR. Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis. Semin Liver Dis. 2019;39(2):195–208. 20. Intagliata NM, Maitland H, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis. Curr Treat Options Gastroenterol. 2016;14(2):247–56. 21. LebretonA, SinegreT, PereiraB, LamblinG, DuronC, Abergel A. Plasmahypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis. J Gastroenterol Hepatol. 2017 Apr;32(4):916–24.